Unclassified · Medical Literature

[Articles] Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Authors
Pablo Mora, Vanita R Aroda, Marisse Asong, Matthias Blüher, Amanda-Louise Fenger Carlander, Morten Kaltoft, Louise Nygaard Vilsen, Julio Rosenstock
Journal
The Lancet
Publication date
2026-07-30
Source
rss_lancet
Original record ID
270231
Summary status
error
Analysis status
error
Original last updated
2026-08-17T07:48:03.000Z

Open original source

Abstract

In people with type 2 diabetes, once-daily oral zenagamtide showed clinically meaningful and significant improvements in HbA1c from baseline to week 36 compared with placebo at all three dose levels (6, 25, and 50 mg). The safety and tolerability of oral zenagamtide was consistent with other GLP-1 and amylin receptor agonists.